The New York Times recently published a good review of what works, and what works less well, in longevity medicine.
When it is done right
At its best, longevity medicine is not about futuristic treatments or quick fixes, but about something more fundamental.
- More time per patient.
- More individualized analysis.
- More focus on prevention instead of reactive care.
In practice: time, attention and continuity. That is also what patients are actually paying for.
This is, at its core, what good medicine has always wanted to be, but rarely had the opportunity to deliver within traditional systems.
"I think in the best-case scenario, longevity medicine is what really good medicine has always aspired to be, but rarely had the tools to deliver" (Dr. Jordan Shlain)
Instead of waiting for disease, you work with trends. A blood sugar level that is starting to drift upward. Lipid markers in the gray zone. Early metabolic changes that are not yet classified as "disease". The logic is simple: why wait until something becomes pathological when you can act earlier?
When it is done wrong
At the same time, the same ambition has opened the door to excesses.
- Tests that lack clinical precision, such as "biological age".
- Treatments with weak evidence: peptides, stem cells, infusions.
- Expensive protocols without clear effect on actual health outcomes.
In some cases there are even reported side effects.
The problem is not only what is offered, but how it is packaged. Advanced biomarkers, large amounts of data and complex reports create a sense of scientific rigor. But more data is not the same thing as better medicine.
Longevity is not necessarily about doing more, but about doing the right things, earlier.
Source: The New York Times
